Login / Signup

Synergy In Vitro of Nikkomycin Z with Azole Against the Invasive Form of Candida albicans.

Gabriele SassDavid J LarwoodDavid A Stevens
Published in: Mycopathologia (2023)
In a previous study, therapeutic activity of nikkomycin Z (NZ) in a model of invasive candidiasis did not appear to correlate with lesser activity in vitro (using classical MIC methods) with planktonic organisms. However, NZ potency was much greater assaying activity in vitro against germ tubes, the initiator of the invasive mycelial form of the fungus, as occurs in infected tissues. Synergy has been demonstrated for NZ and other drugs, notably fluconazole (the most commonly used drug against candidiasis), in planktonic testing, which correlated with results in vivo. This raised the question whether activity shown by NZ alone against germ tubes would be reflected in drug combinations, and even whether synergy testing against germ tubes might be a better correlate of synergy in future in vivo studies. We show in this study significant NZ synergy with fluconazole against germ tubes, for several C. albicans isolates, with testing in many drug ratios. This observation opens the way for further explorations of this method of susceptibility testing for synergy, and correlation with combination therapy against candidiasis.
Keyphrases
  • candida albicans
  • biofilm formation
  • combination therapy
  • gene expression
  • drug induced
  • current status
  • pseudomonas aeruginosa
  • staphylococcus aureus
  • cystic fibrosis
  • case control